Skip to menu Skip to content Skip to footer

2024

Journal Article

CBL0137 and NKG2A blockade: a novel immuno-oncology combination therapy for Myc-overexpressing triple-negative breast cancers

Raninga, Prahlad V., Zeng, Bijun, Moi, Davide, Trethowan, Ethan, Saletta, Federica, Venkat, Pooja, Mayoh, Chelsea, D’Souza, Rochelle C. J., Day, Bryan W., Shai-Hee, Tyler, Vittorio, Orazio, Mazzieri, Roberta, Dolcetti, Riccardo and Khanna, Kum Kum (2024). CBL0137 and NKG2A blockade: a novel immuno-oncology combination therapy for Myc-overexpressing triple-negative breast cancers. Oncogene 6579, 1-1. doi: 10.1038/s41388-024-03259-y

CBL0137 and NKG2A blockade: a novel immuno-oncology combination therapy for Myc-overexpressing triple-negative breast cancers

2024

Journal Article

Targeting chromosomal instability and aneuploidy in cancer

Bhatia, Sugandha, Khanna, Kum Kum and Duijf, Pascal H.G. (2024). Targeting chromosomal instability and aneuploidy in cancer. Trends in Pharmacological Sciences, 45 (3), 210-224. doi: 10.1016/j.tips.2024.01.009

Targeting chromosomal instability and aneuploidy in cancer

2024

Journal Article

Defining the relationship between cellular and extracellular vesicle (EV) content in breast cancer via an integrative multi‐omic analysis

Lane, Rebecca E., Korbie, Darren, Khanna, Kum Kum, Mohamed, Ahmed, Hill, Michelle M. and Trau, Matt (2024). Defining the relationship between cellular and extracellular vesicle (EV) content in breast cancer via an integrative multi‐omic analysis. Proteomics, 24 (11) e2300089, 1-18. doi: 10.1002/pmic.202300089

Defining the relationship between cellular and extracellular vesicle (EV) content in breast cancer via an integrative multi‐omic analysis

2023

Journal Article

COMMD3 loss drives invasive breast cancer growth by modulating copper homeostasis

Hancock, Janelle L., Kalimutho, Murugan, Straube, Jasmin, Lim, Malcolm, Gresshoff, Irma, Saunus, Jodi M., Lee, Jason S., Lakhani, Sunil R., Simpson, Kaylene J., Bush, Ashley I., Anderson, Robin L. and Khanna, Kum Kum (2023). COMMD3 loss drives invasive breast cancer growth by modulating copper homeostasis. Journal of Experimental and Clinical Cancer Research, 42 (1) 90, 1-16. doi: 10.1186/s13046-023-02663-8

COMMD3 loss drives invasive breast cancer growth by modulating copper homeostasis

2023

Journal Article

Combined thioredoxin reductase and glutaminase inhibition exerts synergistic anti-tumor activity in MYC-high high-grade serous ovarian carcinoma

Raninga, Prahlad V., He, Yaowu, Datta, Keshava K., Lu, Xue, Maheshwari, Uma R., Venkat, Pooja, Mayoh, Chelsea, Gowda, Harsha, Kalimutho, Murugan, Hooper, John D. and Khanna, Kum Kum (2023). Combined thioredoxin reductase and glutaminase inhibition exerts synergistic anti-tumor activity in MYC-high high-grade serous ovarian carcinoma. Molecular Therapy, 31 (3) 212011, 729-743. doi: 10.1016/j.ymthe.2022.12.011

Combined thioredoxin reductase and glutaminase inhibition exerts synergistic anti-tumor activity in MYC-high high-grade serous ovarian carcinoma

2023

Journal Article

Alpha-B-Crystallin overexpression is sufficient to promote tumorigenesis and metastasis in mice

Rashidieh, Behnam, Bain, Amanda Louise, Tria, Simon Manuel, Sharma, Sowmya, Stewart, Cameron Allan, Simmons, Jacinta Ley, Apaja, Pirjo M., Duijf, Pascal H. G., Finnie, John and Khanna, Kum Kum (2023). Alpha-B-Crystallin overexpression is sufficient to promote tumorigenesis and metastasis in mice. Experimental Hematology and Oncology, 12 (1) 4, 1-4. doi: 10.1186/s40164-022-00365-z

Alpha-B-Crystallin overexpression is sufficient to promote tumorigenesis and metastasis in mice

2022

Journal Article

Epigenome erosion and SOX10 drive neural crest phenotypic mimicry in triple-negative breast cancer

Saunus, Jodi M., De Luca, Xavier M., Northwood, Korinne, Raghavendra, Ashwini, Hasson, Alexander, McCart Reed, Amy E., Lim, Malcolm, Lal, Samir, Vargas, A. Cristina, Kutasovic, Jamie R., Dalley, Andrew J., Miranda, Mariska, Kalaw, Emarene, Kalita-de Croft, Priyakshi, Gresshoff, Irma, Al-Ejeh, Fares, Gee, Julia M. W., Ormandy, Chris, Khanna, Kum Kum, Beesley, Jonathan, Chenevix-Trench, Georgia, Green, Andrew R., Rakha, Emad A., Ellis, Ian O., Nicolau, Dan V., Simpson, Peter T. and Lakhani, Sunil R. (2022). Epigenome erosion and SOX10 drive neural crest phenotypic mimicry in triple-negative breast cancer. npj Breast Cancer, 8 (1) 57, 1-16. doi: 10.1038/s41523-022-00425-x

Epigenome erosion and SOX10 drive neural crest phenotypic mimicry in triple-negative breast cancer

2021

Journal Article

Targeting BRF2 in cancer using repurposed drugs

Rashidieh, Behnam, Molakarimi, Maryam, Mohseni, Ammar, Tria, Simon Manuel, Truong, Hein, Srihari, Sriganesh, Adams, Rachael C., Jones, Mathew, Duijf, Pascal H. G., Kalimutho, Murugan and Khanna, Kum Kum (2021). Targeting BRF2 in cancer using repurposed drugs. Cancers, 13 (15) 3778, 1-28. doi: 10.3390/cancers13153778

Targeting BRF2 in cancer using repurposed drugs

2021

Journal Article

Differential regulation of lacto-/neolacto- glycosphingolipid biosynthesis pathway reveals transcription factors as potential candidates in triple-negative breast cancer

Zeng, Ruichao, Mohamed, Ahmed, Khanna, Kum Kum and Hill, Michelle M. (2021). Differential regulation of lacto-/neolacto- glycosphingolipid biosynthesis pathway reveals transcription factors as potential candidates in triple-negative breast cancer. Cancers, 13 (13) 3330, 1-15. doi: 10.3390/cancers13133330

Differential regulation of lacto-/neolacto- glycosphingolipid biosynthesis pathway reveals transcription factors as potential candidates in triple-negative breast cancer

2021

Journal Article

Cavin3 released from caveolae interacts with BRCA1 to regulate the cellular stress response

McMahon, Kerrie-Ann, Stroud, David A., Gambin, Yann, Tillu, Vikas, Bastiani, Michele, Sierecki, Emma, Polinkovsky, Mark E., Hall, Thomas E., Gomez, Guillermo A., Wu, Yeping, Parat, Marie-Odile, Martel, Nick, Lo, Harriet P., Khanna, Kum Kum, Alexandrov, Kirill, Daly, Roger, Yap, Alpha, Ryan, Michael T. and Parton, Robert G. (2021). Cavin3 released from caveolae interacts with BRCA1 to regulate the cellular stress response. eLife, 10 e61407, 1-35. doi: 10.7554/elife.61407

Cavin3 released from caveolae interacts with BRCA1 to regulate the cellular stress response

2021

Journal Article

WDR62 is required for centriole duplication in spermatogenesis and manchette removal in spermiogenesis

Ho, Uda Y., Feng, Chun-Wei Allen, Yeap, Yvonne Y., Bain, Amanda L., Wei, Zhe, Shohayeb, Belal, Reichelt, Melissa E., Homer, Hayden, Khanna, Kum Kum, Bowles, Josephine and Ng, Dominic C. H. (2021). WDR62 is required for centriole duplication in spermatogenesis and manchette removal in spermiogenesis. Communications Biology, 4 (1) 645, 1-14. doi: 10.1038/s42003-021-02171-5

WDR62 is required for centriole duplication in spermatogenesis and manchette removal in spermiogenesis

2021

Journal Article

CX-5461 enhances the efficacy of APR-246 via induction of DNA damage and replication stress in triple-negative breast cancer

Makhale, Ashwini, Nanayakkara, Devathri, Raninga, Prahlad, Khanna, Kum Kum and Kalimutho, Murugan (2021). CX-5461 enhances the efficacy of APR-246 via induction of DNA damage and replication stress in triple-negative breast cancer. International Journal of Molecular Sciences, 22 (11) 5782, 5782. doi: 10.3390/ijms22115782

CX-5461 enhances the efficacy of APR-246 via induction of DNA damage and replication stress in triple-negative breast cancer

2020

Journal Article

CX-5461 activates the DNA damage response and demonstrates therapeutic efficacy in high-grade serous ovarian cancer

Sanij, Elaine, Hannan, Katherine M., Xuan, Jiachen, Yan, Shunfei, Ahern, Jessica E., Trigos, Anna S., Brajanovski, Natalie, Son, Jinbae, Chan, Keefe T., Kondrashova, Olga, Lieschke, Elizabeth, Wakefield, Matthew J., Frank, Daniel, Ellis, Sarah, Cullinane, Carleen, Kang, Jian, Poortinga, Gretchen, Nag, Purba, Deans, Andrew J., Khanna, Kum Kum, Mileshkin, Linda, McArthur, Grant A., Soong, John, Berns, Els M. J. J., Hannan, Ross D., Scott, Clare L., Sheppard, Karen E. and Pearson, Richard B. (2020). CX-5461 activates the DNA damage response and demonstrates therapeutic efficacy in high-grade serous ovarian cancer. Nature Communications, 11 (1) 2641, 1-18. doi: 10.1038/s41467-020-16393-4

CX-5461 activates the DNA damage response and demonstrates therapeutic efficacy in high-grade serous ovarian cancer

2020

Journal Article

Cep55 overexpression promotes genomic instability and tumorigenesis in mice

Sinha, Debottam, Nag, Purba, Nanayakkara, Devathri, Duijf, Pascal H. G., Burgess, Andrew, Raninga, Prahlad, Smits, Veronique A. J., Bain, Amanda L., Subramanian, Goutham, Wall, Meaghan, Finnie, John. W., Kalimutho, Murugan and Khanna, Kum Kum (2020). Cep55 overexpression promotes genomic instability and tumorigenesis in mice. Communications Biology, 3 (1) 593, 1-16. doi: 10.1038/s42003-020-01304-6

Cep55 overexpression promotes genomic instability and tumorigenesis in mice

2020

Journal Article

Complexities of pharmacogenomic interactions in cancer

Khanna, Kum Kum and Duijf, Pascal H.G. (2020). Complexities of pharmacogenomic interactions in cancer. Molecular & Cellular Oncology, 7 (3) 1735910, 1735910. doi: 10.1080/23723556.2020.1735910

Complexities of pharmacogenomic interactions in cancer

2020

Journal Article

The implication of the SUMOylation pathway in breast cancer pathogenesis and treatment

Rabellino, Andrea and Khanna, Kum Kum (2020). The implication of the SUMOylation pathway in breast cancer pathogenesis and treatment. Critical Reviews in Biochemistry and Molecular Biology, 55 (1), 54-70. doi: 10.1080/10409238.2020.1738332

The implication of the SUMOylation pathway in breast cancer pathogenesis and treatment

2020

Journal Article

Chromosome arm aneuploidies shape tumour evolution and drug response

Shukla, Ankit, Nguyen, Thu H. M., Moka, Sarat B., Ellis, Jonathan J., Grady, John P., Oey, Harald, Cristino, Alexandre S., Khanna, Kum Kum, Kroese, Dirk P., Krause, Lutz, Dray, Eloise, Fink, J. Lynn and Duijf, Pascal H. G. (2020). Chromosome arm aneuploidies shape tumour evolution and drug response. Nature Communications, 11 (1) 449, 449. doi: 10.1038/s41467-020-14286-0

Chromosome arm aneuploidies shape tumour evolution and drug response

2020

Journal Article

Marizomib suppresses triple-negative breast cancer via proteasome and oxidative phosphorylation inhibition

Raninga, Prahlad, Lee, Andy, Sinha, Debottam, Dong, Lan-feng, Datta, Keshava, Lu, Xue, Kalita-de Croft, Priyakshi, Dutt, Mriga, Hill, Michelle M., Pouliot, Normand M., Gowda, Harsha, Kalimutho, Murugan, Neuzil, Jiri and Khanna, Kum Kum (2020). Marizomib suppresses triple-negative breast cancer via proteasome and oxidative phosphorylation inhibition. Theranostics, 10 (12), 5259-5275. doi: 10.7150/thno.42705

Marizomib suppresses triple-negative breast cancer via proteasome and oxidative phosphorylation inhibition

2020

Journal Article

Anticancer activity of a Gold(I) phosphine thioredoxin reductase inhibitor in multiple myeloma

Sze, Jun Hui, Raninga, Prahlad V., Nakamura, Kyohei, Casey, Mika, Khanna, Kum Kum, Berners-Price, Susan J., Di Trapani, Giovanna and Tonissen, Kathryn F. (2020). Anticancer activity of a Gold(I) phosphine thioredoxin reductase inhibitor in multiple myeloma. Redox Biology, 28 101310, 1-12. doi: 10.1016/j.redox.2019.101310

Anticancer activity of a Gold(I) phosphine thioredoxin reductase inhibitor in multiple myeloma

2020

Journal Article

Therapeutic cooperation between auranofin, a thioredoxin reductase inhibitor and anti-PD-L1 antibody for treatment of triple-negative breast cancer

Raninga, Prahlad V., Lee, Andy C., Sinha, Debottam, Shih, Yu-Yin, Mittal, Deepak, Makhale, Ashwini, Bain, Amanda L., Nanayakarra, Devathri, Tonissen, Kathryn F., Kalimutho, Murugan and Khanna, Kum Kum (2020). Therapeutic cooperation between auranofin, a thioredoxin reductase inhibitor and anti-PD-L1 antibody for treatment of triple-negative breast cancer. International Journal of Cancer, 146 (1), 123-136. doi: 10.1002/ijc.32410

Therapeutic cooperation between auranofin, a thioredoxin reductase inhibitor and anti-PD-L1 antibody for treatment of triple-negative breast cancer